Search…

Hengrui Medicine (01276.HK): Marketing authorization application for fluzoparib capsules accepted by EMA

08/10/2026

Zhito Finance APP news, Hengrui Pharmaceuticals (01276.HK) announced that recently, the company received a notice from the European Medicines Agency (EMA), and the EMA has officially confirmed and accepted the company's marketing authorization application for Fluzoparib capsules. This is the company's second independently developed innovative drug for which a marketing application has been submitted to the European Union.

Latest

2 m ago

$PepsiCo (PEP.US)$ Third-quarter net revenue was $25.27 billion, with a market estimate of $24.95 billion; third-quarter operating profit was $4.26 billion, with a market estimate of $4.19 billion; third-quarter core earnings per share were $2.34, with a market estimate of $2.29; full-year organic revenue is expected to grow about 3%, compared with the previous forecast of 2% to 4% growth and a market estimate of 2.53% growth.

3 m ago

Oilfield services company NESR: The project targets annual production of 2,000 tons of battery-grade lithium carbonate. The contract is valued at up to approximately US$200 million, with a term of up to five years.

4 m ago

Antengene-B (06996.HK) repurchased 120,000 shares for HK$403,600 on October 8.

4 m ago

Tongrentang's (600085.SH) subsidiary obtains Hong Kong proprietary Chinese medicine registration certificate for Dingzhi Pills.

5 m ago

PepsiCo (PEP.O) rose about 2% in premarket trading after its third-quarter revenue beat expectations.

See all latest